Literature DB >> 11082459

Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals.

G D Stanwood1, R P Artymyshyn, M P Kung, H F Kung, I Lucki, P McGonigle.   

Abstract

The regional distribution and cellular localization of dopamine D3 receptors in the rat brain was examined using quantitative autoradiography. [(125)I]7-OH-PIPAT bound in a saturable and reversible manner and exhibited subnanomolar affinity for a single population of GTP-insensitive sites. The pharmacological profile was characteristic of cloned D3 receptors and nonspecific binding was uniformly low. The highest levels of D3 receptors were measured in the islands of Calleja, nucleus accumbens, ventral pallidum, substantia nigra, and lobules 9 and 10 of the cerebellum. The high specific activity of this ligand also allowed detection of D3 receptors in other regions, including the serotonergic dorsal and median raphe nuclei, indicating that the distribution of this receptor is more widespread than previously appreciated. The cellular localization of D3 receptors in regions containing dopaminergic cells and terminals was examined by discrete injection of neurotoxins. Lesion of dopaminergic neurons with 6-hydroxydopamine produced 50% decreases in [(125)I]7-OH-PIPAT binding in the nucleus accumbens and substantia nigra. Quinolinic acid lesion of neurons originating in the nucleus accumbens also produced approximately 50% decreases in D3 receptors in the nucleus accumbens, substantia nigra, and ventral pallidum. 5, 7-Dihydroxytryptamine lesion of serotonergic cells and processes produced no changes in [(125)I]7-OH-PIPAT binding. These results demonstrate the presence of D3 receptors in several brain regions not previously identified and suggest that D3 receptors are expressed at somatodendritic and terminal levels of both dopaminergic and nondo-paminergic cells within the mesolimbic dopamine system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082459

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

2.  [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.

Authors:  Jinbin Xu; Babak Hassanzadeh; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2010-06       Impact factor: 2.562

Review 3.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

4.  [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.

Authors:  Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

5.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Authors:  István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

6.  Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.

Authors:  Zhude Tu; Shihong Li; Jinbin Xu; Wenhua Chu; Lynne A Jones; Robert R Luedtke; Robert H Mach
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

7.  Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior.

Authors:  Anne Stößel; Regine Brox; Nirupam Purkayastha; Harald Hübner; Carsten Hocke; Olaf Prante; Peter Gmeiner
Journal:  Bioorg Med Chem       Date:  2017-04-29       Impact factor: 3.641

8.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

9.  Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.

Authors:  Elissa M Strome; Athanasios P Zis; Doris J Doudet
Journal:  J Psychiatry Neurosci       Date:  2007-05       Impact factor: 6.186

10.  Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking.

Authors:  Maram A T M Khaled; Abhiram Pushparaj; Patricia Di Ciano; Jorge Diaz; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.